OFFICE LEASEOffice Lease • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 3rd, 2024 Company Industry JurisdictionThis Office Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between HSPF LA JOLLA COMMONS I INVESTORS LLC, a Delaware limited liability company (“Landlord”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
SELECTED PRODUCT LICENSE AGREEMENT (AB-201)Selected Product License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryTHIS SELECTED PRODUCT LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 29, 2020 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
Private & ConfidentialEmployment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be on December 31, 2021 (the “Start Date”).
Dr. Heather Raymon Private & ConfidentialEmployment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, which will be on or around October 22, 2020 (the “Start Date”).
CONSULTING AGREEMENTConsulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledMay 3rd, 2024 Company Industry JurisdictionTHIS CONSULTING AGREEMENT (the “Agreement”) is sat by and between ARTIVA BIOTHERAPEUTICS, INC. (“Company”) and MEF CONSULTING LLC, a Limited liability company (“Consultant”), effective as of April 3, 2023 (the “Effective Date”).
Re: Employment Offer LetterEmployment Offer Letter • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryOn behalf of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms will be effective as of your start date, September 16th, 2020.
Agreement Confidential QA Controlled Document Master Agreement for Manufacturing Services March 16, 2020 / DCR001 AGR001.01Master Agreement for Manufacturing Services • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryCERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
Amendment No. 1 to Option and License AgreementOption and License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis Amendment No. 1 (this “Amendment”), effective as of June 23, 2020, amends certain provisions of the Option and License Agreement dated September 4, 2019, between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
OPTION AND LICENSE AGREEMENTOption and License Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 3rd, 2024 Company Industry JurisdictionTHIS OPTION AND LICENSE AGREEMENT (the “Agreement”) is made and entered into as of September 4, 2019 (the “Effective Date”) by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having a place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121, USA, and GREEN CROSS LABCELL CORPORATION, a Korean corporation (“GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of South Korea. Artiva and GCLC are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MASTER RESEARCH SERVICES AGREEMENT (For Selected Products)Master Research Services Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMay 3rd, 2024 Company Industry JurisdictionTHIS MASTER RESEARCH SERVICES AGREEMENT (the “Agreement”) is made as of August 3, 2020 (the “Effective Date”), by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation, having an address of 4747 Executive Drive, Suite 1150, San Diego, CA 92121 (“Artiva”), and GREEN CROSS LABCELL CORPORATION, a Korean corporation, with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 446-850, 16924, Republic of Korea (“GCLC”).
Omnibus AmendmentOmnibus Amendment • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis Omnibus Amendment (this “Amendment”), effective as of February 3, 2022, is entered into by and between ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Artiva”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and GC CELL CORPORATION (F/K/A GREEN CROSS LABCELL CORPORATION), a Korean corporation (“GC Cell” or “GCLC”), with its principal place of business at 107, Ihyeon-ro 30 beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea.
Re: Employment Offer LetterEmployment Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryOn behalf of the Board of Directors of Artiva Biotherapeutics, Inc. (the “Company”), I am pleased to offer you employment under the terms set forth in this offer letter agreement (this “Agreement”). These employment terms are contingent upon Board approval, and will be effective as of your start date, which will be on January 1, 2021 (the “Start Date”).
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryTHIS FIRST AMENDMENT TO LICENSE AGREEMENT (this “First Amendment”) is made as of May 9, 2022, by and between ARE-SD REGION NO. 37, LLC, a Delaware limited liability company (“Licensor”), and ARTIVA BIOTHERAPEUTICS, INC., a Delaware corporation (“Licensee”).
Re: Separation AgreementSeparation Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis letter sets forth the substance of the separation agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
Michael Faerm Re: Separation Agreement Dear Mike:Separation Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis letter sets forth the substance of the separation agreement (the “Agreement”) that Artiva Biotherapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
Amendment No. 1 to Master Agreement for Manufacturing ServicesMaster Agreement for Manufacturing Services • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis Amendment No. 1 (this “Amendment”), effective as of June 16, 2020, amends certain provisions of the Master Agreement for Manufacturing Services dated March 16, 2020, between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 4747 Executive Drive, Suite 1150, San Diego, CA 92121 and Green Cross Cell Corporation, a Korean corporation (“Manufacturer”), with its principal place of business located at 107, lhyeon-ro 30 beon-gil, Giheung- gu, Yongin-si, Gyeonggi-do, 16924, Republic of South Korea (hereinafter the “Original Agreement”).
Amendment No. 1 to Consulting AgreementConsulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis Amendment No. 1 (the “Amendment”), effective as of October 3, 2023, amends certain provisions of the Consulting Agreement dated April 3, 2023 (the “Agreement”), between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 5505 Morehouse Drive, Suite 100, San Diego, CA 92121 and MEF Consulting LLC (“Consultant”).
Amendment No. 1 to Consulting AgreementConsulting Agreement • May 3rd, 2024 • Artiva Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMay 3rd, 2024 Company IndustryThis Amendment No. 1 (the “Amendment”), effective as of September 1, 2023, amends certain provisions of the Consulting Agreement dated March 31, 2023 (the “Agreement”), between Artiva Biotherapeutics, Inc. (“Company”), having its principal place of business at 5505 Morehouse Drive, Suite 100, San Diego, CA 92121 and Peter Flynn (“Consultant”).